Ondansetron Orally Disintegrating Tablets

SOL #: SPE2D2-25-R-0018Solicitation

Overview

Buyer

DEPT OF DEFENSE

Defense Logistics Agency

DLA TROOP SUPPORT

PHILADELPHIA, PA, 19111, United States

Place of Performance

Place of performance not available

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Original Source

https://sam.gov/opp/c175e690919c4f92b0e8bf2e328dda62/view

Timeline

Posted

Aug 7, 2025

Last Updated

Feb 23, 2026

Submission Deadline

Feb 23, 2026, 8:00 PM

Qualification Details

Fit reasons

NAICS alignment with historical contract wins in similar service areas.
Scope strongly matches core technical capabilities and delivery model.

Risks

Past performance thresholds may require one additional teaming partner.
Potential clarification needed on staffing minimums before bid/no-bid.

Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Logistics Agency (DLA) Troop Support has issued a solicitation for Ondansetron Orally Disintegrating Tablets (ODT). This unrestricted opportunity aims to establish a national supply source for the Department of Defense (DoD), Department of Veterans Affairs (VA), Indian Health Service (IHS), and Bureau of Prisons (BoP) through its Pharmaceutical Prime Vendor (PPV) program. An amendment allows for offers of both Bottles and/or Blister Packaging. Proposals are due February 23, 2026, at 3:00 PM EST.

Purpose & Scope

The DLA Troop Support, Directorate of Medical Materiel, seeks to procure Ondansetron ODT in various strengths and quantities to ensure product availability, consistency, and obtain volume-based, committed use pricing. The contract will establish a firm-fixed-price requirements agreement.

Key Requirements

Products: Ondansetron ODT 4 MG Tablet (30 count bottle), Ondansetron ODT 8 MG Tablet (10 count bottle), and Ondansetron ODT 8 MG Tablet (30 count bottle).
Packaging: Unit of use, child-proof closures. Offerors may propose Bottles and/or Blister Packaging. Bottles must have a minimum 100cc volume, cylindrical body, and minimum 5.75" circumference. Labels must be 5.25" x 2" with 0.5" additional space for barcode and expiration date.
Labeling: Bar code labeling at the unit-of-use package level, conforming to GS1-128 or HIBCC standards.
Product Information: Must be registered with RXNorm, First Data Bank, and Medi-Span prior to contract performance.
Regulatory: Offerors must possess FDA approval (NDA, ANDA, or Biologic License) for offered drugs by the solicitation closing date. Manufacturing facilities must have acceptable cGMP status with the FDA.

Contract Details

Type: Firm-fixed-price requirements contract.
Period of Performance: One-year base period with four one-year option periods, for a maximum term of five years.
Contract Performance Date: 45 calendar days after award.
Contract Price Effective Date: No more than 60 calendar days after award.

Submission & Evaluation

Submission Method: Electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS).
Offer Due Date: February 23, 2026, 3:00 PM EST.
Evaluation Criteria: Lowest Price Technically Acceptable (LPTA). Award will be made to the responsible offeror with a technically acceptable proposal and the lowest evaluated aggregate price.
Proposal Structure: Must include a Non-Price Proposal (Volume 1) and a Price Proposal (Volume 2).
Eligibility: Offerors must complete representations and certifications electronically via SAM.gov.

Eligibility & Set-Aside

This acquisition is UNRESTRICTED.
NAICS Code: 325412, Size Standard: 1300 employees.

Additional Notes

A reverse auction may be utilized for price discussions.
Offerors must enter into business-to-business agreements with DLA and VA PPV contractors.
The contract price may be adjusted by distribution fees.